GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Cyclically Adjusted PS Ratio

OptimizeRx (OptimizeRx) Cyclically Adjusted PS Ratio : 4.84 (As of May. 24, 2024)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Cyclically Adjusted PS Ratio?

As of today (2024-05-24), OptimizeRx's current share price is $12.30. OptimizeRx's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $2.54. OptimizeRx's Cyclically Adjusted PS Ratio for today is 4.84.

The historical rank and industry rank for OptimizeRx's Cyclically Adjusted PS Ratio or its related term are showing as below:

OPRX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.16   Med: 13.64   Max: 63.62
Current: 4.84

During the past years, OptimizeRx's highest Cyclically Adjusted PS Ratio was 63.62. The lowest was 3.16. And the median was 13.64.

OPRX's Cyclically Adjusted PS Ratio is ranked worse than
84.96% of 339 companies
in the Healthcare Providers & Services industry
Industry Median: 1.22 vs OPRX: 4.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

OptimizeRx's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.084. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.54 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


OptimizeRx Cyclically Adjusted PS Ratio Historical Data

The historical data trend for OptimizeRx's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Cyclically Adjusted PS Ratio Chart

OptimizeRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.73 25.21 37.94 8.22 5.92

OptimizeRx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.85 6.41 3.37 5.92 4.78

Competitive Comparison of OptimizeRx's Cyclically Adjusted PS Ratio

For the Health Information Services subindustry, OptimizeRx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptimizeRx's Cyclically Adjusted PS Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where OptimizeRx's Cyclically Adjusted PS Ratio falls into.



OptimizeRx Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

OptimizeRx's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=12.30/2.54
=4.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OptimizeRx's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, OptimizeRx's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.084/131.7762*131.7762
=1.084

Current CPI (Mar. 2024) = 131.7762.

OptimizeRx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.184 100.560 0.241
201409 0.234 100.428 0.307
201412 0.225 99.070 0.299
201503 0.195 99.621 0.258
201506 0.223 100.684 0.292
201509 0.247 100.392 0.324
201512 0.208 99.792 0.275
201603 0.182 100.470 0.239
201606 0.197 101.688 0.255
201609 0.182 101.861 0.235
201612 0.224 101.863 0.290
201703 0.217 102.862 0.278
201706 0.291 103.349 0.371
201709 0.318 104.136 0.402
201712 0.411 104.011 0.521
201803 0.420 105.290 0.526
201806 0.427 106.317 0.529
201809 0.419 106.507 0.518
201812 0.541 105.998 0.673
201903 0.398 107.251 0.489
201906 0.507 108.070 0.618
201909 0.354 108.329 0.431
201912 0.507 108.420 0.616
202003 0.519 108.902 0.628
202006 0.599 108.767 0.726
202009 0.706 109.815 0.847
202012 1.086 109.897 1.302
202103 0.697 111.754 0.822
202106 0.753 114.631 0.866
202109 0.886 115.734 1.009
202112 1.032 117.630 1.156
202203 0.768 121.301 0.834
202206 0.771 125.017 0.813
202209 0.839 125.227 0.883
202212 1.146 125.222 1.206
202303 0.761 127.348 0.787
202306 0.813 128.729 0.832
202309 0.982 129.860 0.996
202312 1.596 129.419 1.625
202403 1.084 131.776 1.084

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OptimizeRx  (NAS:OPRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


OptimizeRx Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OptimizeRx (OptimizeRx) Business Description

Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022